Product Datasheet  
APOBEC3D/F Antibody  
Catalog Number: 34926  
Technical:tech@swbio.com  
Information:info@swbio.com  
Description  
  • host_species：  
  • Rabbit
  • Amount：  
  • 100μgμg
  • Swiss-Prot No.：  
  • Swiss-Prot: Q96AK3/Q8IUX4
    NCBI Gene ID: 200316/140564
  • Form of Antibody：  
  • Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
  • Storage：  
  • Store at -20˚C
  • Immunogen：  
  • Synthesized peptide derived from internal of human APOBEC3D/F.
  • reactivity：  
  • Hu
  • appl_detail：  
  • Western blotting: 1:500~1:3000
    Immunohistochemistry: 1:50~1:100
  • other_names：  
  • Probable DNA dC->dU-editing enzyme APOBEC-3D; EC 3.5.4.-; APOBEC3D;
  • Purification：  
  • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
  • Specificity：  
  • The antibody detects endogenous levels of total APOBEC3D/F protein.
  • Applications：  
  • WB IHC
  • Background：  
  • DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. Exhibits antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single-or double-stranded RNA. May inhibit the mobility of LTR and non-LTR retrotransposons.

    Dunham I., Nature 402:489-495(1999).
    Jarmuz A., Genomics 79:285-296(2002).
    Wedekind J.E., Trends Genet. 19:207-216(2003).



 
© Signalway Biotechnology All Rights Reserved.